Filing Flows › Companies › BioMarin Pharmaceutical › Timeline
BioMarin Pharmaceutical stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+8.1% to $56.03
BioMarin Pharmaceutical (BMRN) stock rose 8% over the last 252 sessions, to $56.03. On the way it reported 4 quarters, its insiders filed 2 open-market trades and 1 Form 144 notice of planned sales, and the company filed 9 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 2, 2026 | Earnings | Earnings: beat the EPS estimate by 304.8% | −1.8% (−1.4% vs SPY) | −4.3% (−1.6% vs SPY) | — |
| Sep 30, 2026 | 8-K | Material definitive agreement | −2.6% (−2.8% vs SPY) | −8.3% (−10.2% vs SPY) | −4.2% (−5.1% vs SPY) |
| Sep 14, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.1% (+1.6% vs SPY) | −2.7% (−2.6% vs SPY) | −17.0% (−19.1% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: George Eric Davis plans to sell $1.2M | +3.2% (+2.8% vs SPY) | −0.7% (−0.7% vs SPY) | −10.4% (−10.9% vs SPY) |
| Sep 2, 2026 | Insider sale | Davis George Eric sold $1.2M | +3.2% (+2.8% vs SPY) | −0.7% (−0.7% vs SPY) | −10.4% (−10.9% vs SPY) |
| Aug 31, 2026 | 8-K | Material definitive agreement | +0.9% (+1.2% vs SPY) | +2.8% (+2.7% vs SPY) | −7.7% (−7.3% vs SPY) |
| Aug 18, 2026 | 8-K | Material definitive agreement | +0.5% (+1.2% vs SPY) | −2.4% (−1.2% vs SPY) | −2.9% (−0.5% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 25.8% | +2.6% (+2.7% vs SPY) | +15.9% (+15.6% vs SPY) | +10.3% (+9.9% vs SPY) |
| Jun 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.5% (+3.1% vs SPY) | −1.7% (+0.9% vs SPY) | +6.6% (+7.6% vs SPY) |
| May 7, 2026 | Insider sale | Friberg Gregory R sold $177K | −0.9% (−0.6% vs SPY) | −1.9% (−3.1% vs SPY) | +3.9% (+3.4% vs SPY) |
| May 4, 2026 | Earnings | Earnings: missed the EPS estimate by -16.9% | +2.6% (+2.9% vs SPY) | 0.0% (−2.3% vs SPY) | −1.4% (−6.6% vs SPY) |
| Apr 27, 2026 | 8-K | Material definitive agreement | +1.2% (+1.0% vs SPY) | +1.6% (+0.7% vs SPY) | −0.6% (−5.6% vs SPY) |
| Feb 23, 2026 | Earnings | Earnings: missed the EPS estimate by -156.8% | −1.8% (−0.8% vs SPY) | −3.7% (−3.2% vs SPY) | −15.7% (−10.9% vs SPY) |
| Feb 12, 2026 | 8-K | Material definitive agreement | −0.1% (−0.2% vs SPY) | +6.7% (+5.5% vs SPY) | −4.3% (−2.4% vs SPY) |
| Dec 19, 2025 | 8-K | Material definitive agreement | +16.3% (+15.4% vs SPY) | +14.3% (+12.0% vs SPY) | +8.8% (+7.2% vs SPY) |
| Dec 17, 2025 | 8-K | Directors and officers: departures, appointments, pay | +0.3% (−0.5% vs SPY) | +14.9% (+11.9% vs SPY) | +8.3% (+7.1% vs SPY) |
Insiders’ record here
In the year on the chart, BioMarin Pharmaceutical's insiders reported 0 open-market buys ($0) and 2 sales ($1.3M). Of the 1 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +12.2%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 2.01 Completed acquisition or disposition | 2,671 | +0.1% | 52% | +1.2% | ±1.6% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → BioMarin Pharmaceutical: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.